| Identification | Back Directory | [Name]
Tanomastat | [CAS]
179545-77-8 | [Synonyms]
D03802
TANOMASTAT
Tanomastat (usan/inn)
(S)-4'-Chloro-g-oxo-a-[(phenylthio)methyl][1,1'-biphenyl]-4-butanoic acid
(S)-4-[4-(4-Chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
BAY12-9566,(S)-4Chloro-g-oxo-a-[(phenylthio)methyl][1,1biphenyl]-4-butanoicAcid
(S)-4-(4'-Chloro-[1,1'-biphenyl]-4-yl)-4-oxo-2-((phenylthio)methyl)butanoic acid | [Molecular Formula]
C23H19ClO3S | [MDL Number]
MFCD00948600 | [MOL File]
179545-77-8.mol | [Molecular Weight]
410.91 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
110-110.5°C | [Boiling point ]
620.1±55.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Acetone (Slightly), Chloroform (Slightly), Ethyl Acetate (Slightly) | [form ]
Solid | [pka]
4.01±0.23(Predicted) | [color ]
White to Off-White | [CAS DataBase Reference]
179545-77-8 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
A Matrix Metalloproteinase inhibitor. An angiogenesis inhibitor.
Optical Rotation +82?(C 1.5 acetone) | [Uses]
Tanomastat is an orally available, non-peptidic inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (Kis = 11, 143, and 301 nM, respectively). It is active in various animal models of tumor metastasis and has been used in a phase III clinical trial in pancreatic, SCLC, NSCLC, and ovarian cancer patients. | [Definition]
ChEBI:Tanomastat is an organochlorine compound and a member of biphenyls. | [storage]
Store at -20°C |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|